Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: Lynparza poised for expansion in prostate cancer; zuranolone faces challenges in depression; Novartis transfers products and cuts jobs in India; US call to build Alzheimer’s infrastructure; and Indian legal row over COVID spray product.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 18 February 2022, including: Lynparza poised for expansion in prostate cancer; zuranolone faces challenges in depression; Novartis AG transfers products and cuts jobs in India; US call to build Alzheimer’s infrastructure; and Indian legal row over COVID spray product.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "Lynparza On Track For Broad Frontline Use In Prostate Cancer" - Scrip, 15 Feb, 2022.)

(Also see "Sage/Biogen Depression Data Likely To Prolong Commercial Debate" - Scrip, 16 Feb, 2022.)

(Also see "Novartis-Dr Reddy’s Sales Pact, Job Cuts: Are Foreign Firms Altering India Push?" - Scrip, 14 Feb, 2022.)

(Also see "Work Now To Build The Alzheimer's Commercial Landscape, McClellan Advises" - Scrip, 15 Feb, 2022.)

(Also see "SaNOtize, Lupin In Legal Row Concerning COVID-19 Nasal Spray" - Scrip, 14 Feb, 2022.)

 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel